Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.

Yaqin ZhangRuofei ChenYangyang JiaMingwei Chen Zongwen Shuai

Published in: Drug design, development and therapy (2021)

The GLP-1R agonist exenatide can inhibit the activation state of platelets in patients with T2DM and inhibit thrombosis, which is beneficial to reduce the risk of cardiovascular events.

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
pulmonary embolism
type diabetes
skeletal muscle
adipose tissue